A diabetes type 2 model laboratory animal is disclosed which comprises cells over-expressing GPR40 under the control of the Ipfl/Pdx 1 promoter. Also disclosed is the use of the model animal for the identification of agonists or antagonists towards GPR40, useful for the development of pharmaceuticals towards treatment of the disease.